ID   SCN4A_RAT               Reviewed;        1840 AA.
AC   P15390; O70611;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   02-OCT-2024, entry version 176.
DE   RecName: Full=Sodium channel protein type 4 subunit alpha {ECO:0000305};
DE   AltName: Full=Mu-1;
DE   AltName: Full=SkM1 {ECO:0000303|PubMed:9613589};
DE   AltName: Full=Sodium channel protein skeletal muscle subunit alpha;
DE   AltName: Full=Sodium channel protein type IV subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.4 {ECO:0000305|PubMed:28012039};
GN   Name=Scn4a {ECO:0000312|RGD:3636};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=2559760; DOI=10.1016/0896-6273(89)90113-x;
RA   Trimmer J.S., Cooperman S.S., Tomiko S.A., Zhou J., Crean S.M., Boyle M.B.,
RA   Kallen R.G., Sheng Z., Barchi R.L., Sigworth F.J., Goodman R.H.,
RA   Agnew W.S., Mandel G.;
RT   "Primary structure and functional expression of a mammalian skeletal muscle
RT   sodium channel.";
RL   Neuron 3:33-49(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANTS ILE-120;
RP   HIS-916; CYS-1202; ASP-1257; GLY-1755 AND LYS-1803.
RC   STRAIN=COP; TISSUE=Prostate;
RX   PubMed=9613589; DOI=10.1016/s0014-5793(98)00378-0;
RA   Diss J.K.J., Stewart D., Fraser S.P., Black J.A., Dibb-Hajj S.,
RA   Waxman S.G., Archer S.N., Djamgoz M.B.A.;
RT   "Expression of skeletal muscle-type voltage-gated Na+ channel in rat and
RT   human prostate cancer cell lines.";
RL   FEBS Lett. 427:5-10(1998).
RN   [3]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, ACTIVITY REGULATION,
RP   AND MUTAGENESIS OF TYR-401.
RX   PubMed=16303569; DOI=10.1016/j.cub.2005.10.068;
RA   Venkatesh B., Lu S.Q., Dandona N., See S.L., Brenner S., Soong T.W.;
RT   "Genetic basis of tetrodotoxin resistance in pufferfishes.";
RL   Curr. Biol. 15:2069-2072(2005).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [5]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF 1240-MET-ILE-1241.
RX   PubMed=23077250; DOI=10.1073/pnas.1206952109;
RA   Walker J.R., Novick P.A., Parsons W.H., McGregor M., Zablocki J.,
RA   Pande V.S., Du Bois J.;
RT   "Marked difference in saxitoxin and tetrodotoxin affinity for the human
RT   nociceptive voltage-gated sodium channel (Nav1.7) [corrected].";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:18102-18107(2012).
RN   [6]
RP   ERRATUM OF PUBMED:23077250.
RA   Walker J.R., Novick P.A., Parsons W.H., McGregor M., Zablocki J.,
RA   Pande V.S., Du Bois J.;
RL   Proc. Natl. Acad. Sci. U.S.A. 109:21551-21551(2012).
RN   [7]
RP   TRANSPORTER ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G., Wickenden A.D.,
RA   Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [8]
RP   FUNCTION, TRANSPORTER ACTIVITY, INTERACTION WITH SCN1B, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF 1303-ILE--MET-1305.
RX   PubMed=28012039; DOI=10.1007/s00249-016-1193-3;
RA   Sanchez-Solano A., Islas A.A., Scior T., Paiz-Candia B.,
RA   Millan-PerezPena L., Salinas-Stefanon E.M.;
RT   "Characterization of specific allosteric effects of the Na+ channel beta1
RT   subunit on the Nav1.4 isoform.";
RL   Eur. Biophys. J. 46:485-494(2017).
RN   [9]
RP   MUTAGENESIS OF TYR-1379 AND ASN-1380.
RX   PubMed=28428547; DOI=10.1038/s41598-017-01129-0;
RA   Wingerd J.S., Mozar C.A., Ussing C.A., Murali S.S., Chin Y.K.,
RA   Cristofori-Armstrong B., Durek T., Gilchrist J., Vaughan C.W., Bosmans F.,
RA   Adams D.J., Lewis R.J., Alewood P.F., Mobli M., Christie M.J., Rash L.D.;
RT   "The tarantula toxin beta/delta-TRTX-Pre1a highlights the importance of the
RT   S1-S2 voltage-sensor region for sodium channel subtype selectivity.";
RL   Sci. Rep. 7:974-988(2017).
RN   [10]
RP   STRUCTURE BY NMR OF 1567-1594.
RX   PubMed=30389410; DOI=10.1016/j.bmc.2018.10.012;
RA   Niitsu A., Egawa A., Ikeda K., Tachibana K., Fujiwara T.;
RT   "Veratridine binding to a transmembrane helix of sodium channel Nav1.4
RT   determined by solid-state NMR.";
RL   Bioorg. Med. Chem. 26:5644-5653(2018).
CC   -!- FUNCTION: Pore-forming subunit of Nav1.4, a voltage-gated sodium (Nav)
CC       channel that directly mediates the depolarizing phase of action
CC       potentials in excitable membranes. Navs, also called VGSCs (voltage-
CC       gated sodium channels) or VDSCs (voltage-dependent sodium channels),
CC       operate by switching between closed and open conformations depending on
CC       the voltage difference across the membrane. In the open conformation
CC       they allow Na(+) ions to selectively pass through the pore, along their
CC       electrochemical gradient. The influx of Na+ ions provokes membrane
CC       depolarization, initiating the propagation of electrical signals
CC       throughout cells and tissues (PubMed:16303569, PubMed:2559760,
CC       PubMed:28012039). Highly expressed in skeletal muscles, Nav1.4
CC       generates the action potential crucial for muscle contraction (By
CC       similarity). {ECO:0000250|UniProtKB:P35499,
CC       ECO:0000269|PubMed:16303569, ECO:0000269|PubMed:2559760,
CC       ECO:0000269|PubMed:28012039}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Na(+)(in) = Na(+)(out); Xref=Rhea:RHEA:34963,
CC         ChEBI:CHEBI:29101; Evidence={ECO:0000269|PubMed:16303569,
CC         ECO:0000269|PubMed:24497506, ECO:0000269|PubMed:28012039};
CC   -!- ACTIVITY REGULATION: Potently inhibited by tetrodotoxin and saxitoxin
CC       (PubMed:16303569, PubMed:23077250). Inhibited by the conotoxin GVIIJ
CC       (PubMed:24497506). {ECO:0000269|PubMed:16303569,
CC       ECO:0000269|PubMed:23077250, ECO:0000269|PubMed:24497506}.
CC   -!- SUBUNIT: The Nav1.4 voltage-gated sodium channel consists of an ion-
CC       conducting alpha subunit SCN4A which is functional on its own and a
CC       regulatory beta subunit SCN1B (PubMed:28012039). SCN1B strongly
CC       enhances the presence of SCN4A at the cell surface (By similarity).
CC       SCN1B is also required for rapid channel inactivation and recovery
CC       after inactivation. It prevents the decrease of channel activity in
CC       response to repetitive, high-frequency depolarizations
CC       (PubMed:28012039). Interacts with the syntrophins SNTA1, SNTB1 and
CC       SNTB2 (via PDZ domain); probably links SCN4A to the actin cytoskeleton
CC       and the extracellular matrix via the dystrophin-associated protein
CC       complex and regulates its localization in muscle cells (By similarity).
CC       Interacts with TMEM233; probable regulator of the channel (By
CC       similarity). {ECO:0000250|UniProtKB:P35499,
CC       ECO:0000269|PubMed:28012039}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16303569,
CC       ECO:0000269|PubMed:2559760, ECO:0000269|PubMed:28012039}; Multi-pass
CC       membrane protein {ECO:0000250|UniProtKB:P35499}.
CC   -!- TISSUE SPECIFICITY: Detected in skeletal muscle.
CC       {ECO:0000269|PubMed:9613589}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1, S2, S3, S5, S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at every
CC       third position. {ECO:0000250|UniProtKB:P35499}.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.4/SCN4A subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M26643; AAA41682.1; -; mRNA.
DR   EMBL; Y17153; CAA76659.1; -; mRNA.
DR   PIR; JN0007; CHRTM1.
DR   RefSeq; NP_037310.1; NM_013178.1.
DR   PDB; 5JR0; NMR; -; A=1567-1594.
DR   PDB; 6MUE; X-ray; 1.90 A; B=1716-1744.
DR   PDBsum; 5JR0; -.
DR   PDBsum; 6MUE; -.
DR   AlphaFoldDB; P15390; -.
DR   SMR; P15390; -.
DR   BioGRID; 247751; 2.
DR   STRING; 10116.ENSRNOP00000016841; -.
DR   BindingDB; P15390; -.
DR   ChEMBL; CHEMBL3509; -.
DR   DrugCentral; P15390; -.
DR   GuidetoPHARMACOLOGY; 581; -.
DR   GlyCosmos; P15390; 9 sites, No reported glycans.
DR   GlyGen; P15390; 9 sites.
DR   iPTMnet; P15390; -.
DR   PhosphoSitePlus; P15390; -.
DR   PaxDb; 10116-ENSRNOP00000016841; -.
DR   ABCD; P15390; 1 sequenced antibody.
DR   GeneID; 25722; -.
DR   KEGG; rno:25722; -.
DR   UCSC; RGD:3636; rat.
DR   AGR; RGD:3636; -.
DR   CTD; 6329; -.
DR   RGD; 3636; Scn4a.
DR   eggNOG; KOG2301; Eukaryota.
DR   InParanoid; P15390; -.
DR   OrthoDB; 1110761at2759; -.
DR   PhylomeDB; P15390; -.
DR   PRO; PR:P15390; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; ISS:UniProtKB.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; ISS:UniProtKB.
DR   GO; GO:0015871; P:choline transport; IMP:RGD.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0006812; P:monoatomic cation transport; IMP:RGD.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0006813; P:potassium ion transport; IMP:RGD.
DR   GO; GO:0100001; P:regulation of skeletal muscle contraction by action potential; ISS:UniProtKB.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; IDA:RGD.
DR   CDD; cd13433; Na_channel_gate; 1.
DR   Gene3D; 1.10.287.70; -; 4.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.20.5.1190; iswi atpase; 1.
DR   Gene3D; 1.20.120.350; Voltage-gated potassium channels. Chain C; 4.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR008052; Na_channel_a4su_mammal.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR044564; Na_chnl_inactivation_gate.
DR   InterPro; IPR010526; Na_trans_assoc_dom.
DR   InterPro; IPR043203; VGCC_Ca_Na.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR10037:SF223; SODIUM CHANNEL PROTEIN TYPE 4 SUBUNIT ALPHA; 1.
DR   PANTHER; PTHR10037; VOLTAGE-GATED CATION CHANNEL CALCIUM AND SODIUM; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01665; NACHANNEL4.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 4.
DR   PROSITE; PS50096; IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; Glycoprotein; Ion channel;
KW   Ion transport; Membrane; Phosphoprotein; Reference proteome; Repeat;
KW   Sodium; Sodium channel; Sodium transport; Transmembrane;
KW   Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN           1..1840
FT                   /note="Sodium channel protein type 4 subunit alpha"
FT                   /id="PRO_0000048496"
FT   TOPO_DOM        1..131
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        132..150
FT                   /note="Helical; Name=S1 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        151..157
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        158..178
FT                   /note="Helical; Name=S2 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        179..192
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        193..210
FT                   /note="Helical; Name=S3 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        211..216
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        217..233
FT                   /note="Helical; Name=S4 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        234..252
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        253..272
FT                   /note="Helical; Name=S5 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        273..385
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        386..410
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        411..417
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        418..438
FT                   /note="Helical; Name=S6 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        439..572
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        573..591
FT                   /note="Helical; Name=S1 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        592..602
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        603..622
FT                   /note="Helical; Name=S2 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        623..636
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        637..656
FT                   /note="Helical; Name=S3 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        657..658
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        659..676
FT                   /note="Helical; Name=S4 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        677..692
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        693..711
FT                   /note="Helical; Name=S5 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        712..740
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        741..761
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        762..772
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        773..791
FT                   /note="Helical; Name=S6 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        792..1025
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1026..1043
FT                   /note="Helical; Name=S1 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1044..1056
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1057..1075
FT                   /note="Helical; Name=S2 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1076..1089
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1090..1108
FT                   /note="Helical; Name=S3 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1109..1116
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1117..1135
FT                   /note="Helical; Name=S4 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1136..1152
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1153..1172
FT                   /note="Helical; Name=S5 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1173..1223
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        1224..1245
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1246..1262
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1263..1284
FT                   /note="Helical; Name=S6 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1285..1347
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1348..1365
FT                   /note="Helical; Name=S1 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1366..1376
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1377..1395
FT                   /note="Helical; Name=S2 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1396..1407
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1408..1425
FT                   /note="Helical; Name=S3 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1426..1438
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1439..1455
FT                   /note="Helical; Name=S4 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1456..1474
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1475..1492
FT                   /note="Helical; Name=S5 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1493..1514
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        1515..1537
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1538..1567
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1568..1590
FT                   /note="Helical; Name=S6 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   TOPO_DOM        1591..1840
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REPEAT          113..448
FT                   /note="I"
FT                   /evidence="ECO:0000305"
FT   REPEAT          554..826
FT                   /note="II"
FT                   /evidence="ECO:0000305"
FT   REPEAT          1006..1319
FT                   /note="III"
FT                   /evidence="ECO:0000305"
FT   REPEAT          1328..1626
FT                   /note="IV"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1720..1749
FT                   /note="IQ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT   REGION          36..63
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          481..522
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          854..884
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          925..983
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1303..1305
FT                   /note="Important for rapid channel inactivation"
FT                   /evidence="ECO:0000269|PubMed:28012039"
FT   REGION          1775..1840
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        36..59
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        481..499
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        864..884
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        968..983
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1775..1796
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1811..1827
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            401
FT                   /note="Important for inhibition by tetrodotoxin"
FT                   /evidence="ECO:0000269|PubMed:16303569"
FT   MOD_RES         487
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        288
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        291
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        297
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        303
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        309
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        315
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        327
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        356
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        280..354
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   DISULFID        363..369
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   DISULFID        725..731
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   DISULFID        763..772
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   DISULFID        1546..1561
FT                   /evidence="ECO:0000250|UniProtKB:P35499"
FT   VARIANT         120
FT                   /note="V -> I (in strain: COP; prostatic cancer cell
FT                   lines)"
FT                   /evidence="ECO:0000269|PubMed:9613589"
FT   VARIANT         916
FT                   /note="Q -> H (in strain: COP; prostatic cancer cell
FT                   lines)"
FT                   /evidence="ECO:0000269|PubMed:9613589"
FT   VARIANT         1202
FT                   /note="S -> C (in strain: COP; prostatic cancer cell
FT                   lines)"
FT                   /evidence="ECO:0000269|PubMed:9613589"
FT   VARIANT         1257
FT                   /note="H -> D (in strain: COP; prostatic cancer cell
FT                   lines)"
FT                   /evidence="ECO:0000269|PubMed:9613589"
FT   VARIANT         1755
FT                   /note="D -> G (in strain: COP; prostatic cancer cell
FT                   lines)"
FT                   /evidence="ECO:0000269|PubMed:9613589"
FT   VARIANT         1803
FT                   /note="E -> K (in strain: COP; prostatic cancer cell
FT                   lines)"
FT                   /evidence="ECO:0000269|PubMed:9613589"
FT   MUTAGEN         401
FT                   /note="Y->C,N: Strongly reduced sensitivity to
FT                   tetrodotoxin."
FT                   /evidence="ECO:0000269|PubMed:16303569"
FT   MUTAGEN         1240..1241
FT                   /note="MD->TI: Strongly reduced sensitivity to saxitoxin."
FT                   /evidence="ECO:0000269|PubMed:23077250"
FT   MUTAGEN         1303..1305
FT                   /note="Missing: Loss of rapid channel inactivation."
FT                   /evidence="ECO:0000269|PubMed:28012039"
FT   MUTAGEN         1379
FT                   /note="Y->S: Become sensitive to the spider beta/delta-
FT                   theraphotoxin-Pre1a, which inhibits inactivation of the
FT                   channel."
FT                   /evidence="ECO:0000269|PubMed:28428547"
FT   MUTAGEN         1380
FT                   /note="N->R: No change in sensitivity to the spider
FT                   beta/delta-theraphotoxin-Pre1a."
FT                   /evidence="ECO:0000269|PubMed:28428547"
FT   HELIX           1569..1594
FT                   /evidence="ECO:0007829|PDB:5JR0"
FT   HELIX           1722..1732
FT                   /evidence="ECO:0007829|PDB:6MUE"
SQ   SEQUENCE   1840 AA;  208867 MW;  C5DC09D93DD9FAD6 CRC64;
     MASSSLPNLV PPGPHCLRPF TPESLAAIEQ RAVEEEARLQ RNKQMEIEEP ERKPRSDLEA
     GKNLPLIYGD PPPEVIGIPL EDLDPYYSDK KTFIVLNKGK AIFRFSATPA LYLLSPFSIV
     RRVAIKVLIH ALFSMFIMIT ILTNCVFMTM SNPPSWSKHV EYTFTGIYTF ESLIKMLARG
     FCIDDFTFLR DPWNWLDFSV ITMAYVTEFV DLGNISALRT FRVLRALKTI TVIPGLKTIV
     GALIQSVKKL SDVMILTVFC LSVFALVGLQ LFMGNLRQKC VRWPPPMNDT NTTWYGNDTW
     YSNDTWYGND TWYINDTWNS QESWAGNSTF DWEAYINDEG NFYFLEGSND ALLCGNSSDA
     GHCPEGYECI KAGRNPNYGY TSYDTFSWAF LALFRLMTQD YWENLFQLTL RAAGKTYMIF
     FVVIIFLGSF YLINLILAVV AMAYAEQNEA TLAEDQEKEE EFQQMLEKYK KHQEELEKAK
     AAQALESGEE ADGDPTHNKD CNGSLDASGE KGPPRPSCSA DSAISDAMEE LEEAHQKCPP
     WWYKCAHKVL IWNCCAPWVK FKHIIYLIVM DPFVDLGITI CIVLNTLFMA MEHYPMTEHF
     DNVLSVGNLV FTGIFTAEMV LKLIAMDPYE YFQQGWNIFD SFIVTLSLVE LGLANVQGLS
     VLRSFRLLRV FKLAKSWPTL NMLIKIIGNS VGALGNLTLV LAIIVFIFAV VGMQLFGKSY
     KECVCKIASD CNLPRWHMND FFHSFLIVFR ILCGEWIETM WDCMEVAGQA MCLTVFLMVM
     VIGNLVVLNL FLALLLSSFS ADSLAASDED GEMNNLQIAI GRIKWGIGFA KTFLLGLLRG
     KILSPKEIIL SLGEPGGAGE NAEESTPEDE KKEPPPEDKE LKDNHILNHV GLTDGPRSSI
     ELDHLNFINN PYLTIQVPIA SEESDLEMPT EEETDAFSEP EDIKKPLQPL YDGNSSVCST
     ADYKPPEEDP EEQAEENPEG EQPEECFTEA CVKRCPCLYV DISQGRGKMW WTLRRACFKI
     VEHNWFETFI VFMILLSSGA LAFEDIYIEQ RRVIRTILEY ADKVFTYIFI LEMLLKWVAY
     GFKVYFTNAW CWLDFLIVDV SIISLVANWL GYSELGPIKS LRTLRALRPL RALSRFEGMR
     VVVNALLGAI PSIMNVLLVC LIFWLIFSIM GVNLFAGKFY YCVNTTTSER FDISVVNNKS
     ESESLMYTGQ VRWMNVKVNY DNVGLGYLSL LQVATFKGWM DIMYAAVDSR EKEEQPHYEV
     NLYMYLYFVI FIIFGSFFTL NLFIGVIIDN FNQQKKKFGG KDIFMTEEQK KYYNAMKKLG
     SKKPQKPIPR PQNKIQGMVY DFVTKQVFDI SIMILICLNM VTMMVETDDQ SQLKVDILYN
     INMVFIIIFT GECVLKMFAL RHYYFTIGWN IFDFVVVILS IVGLALSDLI QKYFVSPTLF
     RVIRLARIGR VLRLIRGAKG IRTLLFALMM SLPALFNIGL LLFLVMFIYS IFGMSNFAYV
     KKESGIDDMF NFETFGNSII CLFEITTSAG WDGLLNPILN SGPPDCDPTL ENPGTNVRGD
     CGNPSIGICF FCSYIIISFL IVVNMYIAII LENFNVATEE SSEPLSEDDF EMFYETWEKF
     DPDATQFIDY SRLSDFVDTL QEPLKIAKPN KIKLITLDLP MVPGDKIHCL DILFALTKEV
     LGDSGEMDAL KQTMEEKFMA ANPSKVSYEP ITTTLKRKQE EVCAIKIQRA YRRHLLQRSV
     KQASYMYRHS QDGNDDGAPE KEGLLANTMN KMYGHEKEGD GVQSQGEEEK ASTEDAGPTV
     EPEPTSSSDT ALTPSPPPLP PSSSPPQGQT VRPGVKESLV
//
